Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.

about

Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function.

P2860

Q41448138-C1571C28-5E7E-4D79-A240-41E11713AE04

P2860

Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.

Item

http://www.wikidata.org/entity/Q38714376

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Problems in the Descriptions o ...... ndations for Improved Clarity.

@en

type

Item

label

Problems in the Descriptions o ...... ndations for Improved Clarity.

@en

prefLabel

Problems in the Descriptions o ...... ndations for Improved Clarity.

@en

P1476

Problems in the Descriptions o ...... ndations for Improved Clarity.

@en

P2093

Douglas Gazarian

http://www.w3.org/2001/XMLSchema#string

Emily Walsh

http://www.w3.org/2001/XMLSchema#string

Heather L Clark

http://www.w3.org/2001/XMLSchema#string

Lia K Rosenstein

http://www.w3.org/2001/XMLSchema#string

Mark Zimmerman

http://www.w3.org/2001/XMLSchema#string

Matthew Multach

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder

A rating scale for depression

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

A new depression scale designed to be sensitive to change

Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.

P2888

s40263-016-0314-y

P304

185-191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40263-016-0314-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

292154040

http://www.w3.org/2001/XMLSchema#string

P698

26818632

http://www.w3.org/2001/XMLSchema#string

Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.

about

P2860

P2860

Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698